Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: a Retrospective Cohort Study Based on the AIFA Monitoring Registries
Source : https://pubmed.ncbi.nlm.nih.gov/37850449/
Background Information on the real-world use of proprotein convertase subtilisin kexin 9 inhibitors (PCKS9is) in familial hypercholesterolemia are limited.
A group of international researchers showed that the full achievement of European Atherosclerosis Society/European Society of Cardiology LDL‐C goals should require a lower threshold for PCSK9 inhibitor initiation and eventually combination of multiple lipid‐lowering therapies.
Share
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: a Scientific Statement From the American Heart Association
Source : https://pubmed.ncbi.nlm.nih.gov/37706297/
The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol lowering or lipid lowering exerts toxic effects...
The risk of a hemorrhagic stroke associated with statin therapy in patients without a history of cerebrovascular disease is nonsignificant, and achieving very low levels of low-density lipoprotein cholesterol does not increase that risk.
Share
The Effects of Statin Therapy on Aneurysm Size, Growth Rate, and Matrix Metalloproteinases-9 Levels in Patients With Aortic Aneurysm: a Systematic Review and Meta-Analysis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575821/
Aortic aneurysm enlargement over time causes rupture, which frequently results in death. The family of proteases known as matrix metalloproteinases (MMP) is assumed to be proteolytic activity involved in the...
Overall, this meta-analysis demonstrates that statin medication is considerably helpful in reducing aneurysm diameter size and aneurysmal growth rate in individuals with aortic aneurysm.
Share
Evolocumab in Paediatric Heterozygous Familial Hypercholesterolaemia: Cognitive Function During 80 Weeks of Open-Label Extension Treatment
Source : https://pubmed.ncbi.nlm.nih.gov/37855448/
In paediatric patients with FH, 80 weeks of open-label evolocumab treatment had no negative impact on cognitive function.
Because cholesterol is important for development and adequate function of the brain, there is a concern that lowering cholesterol in children may affect mental ability. In this study, researchers tested whether treating children with evolocumab for 80 weeks affected mental ability in performing several tasks.
Share
PCSK9 Inhibition Ameliorates Experimental Autoimmune Myocarditis by Reducing TH17 Cell Differentiation Through LDLR/STAT-3/ROR-γT Pathway
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923012870?via=ihub
Proprotein convertase subtilisin kexin type 9 (PCSK9) was characterized as a protein regulating circulating cholesterol metabolism; however, recent st...
PCSK9 inhibition ameliorated the severity of EAM mice by reducing Th17 cell differentiation. PCSK9 is a promising target for treating myocarditis.
Share